<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992446</url>
  </required_header>
  <id_info>
    <org_study_id>2292.00</org_study_id>
    <secondary_id>NCI-2009-01302</secondary_id>
    <secondary_id>FH 2292/X05287</secondary_id>
    <secondary_id>X05287</secondary_id>
    <secondary_id>2292.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00992446</nct_id>
  </id_info>
  <brief_title>Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma</brief_title>
  <official_title>Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well bortezomib and vorinostat work in
      treating patients with non-Hodgkin lymphoma (NHL) after patients' own stem cell (autologous)
      transplant. Bortezomib and vorinostat in the laboratory may stop the growth of lymphoma cells
      and make them more likely to die by blocking some of the enzymes needed for cell growth.
      Giving bortezomib together with vorinostat after an autologous stem cell transplant may thus
      kill lymphoma cells that remain after transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess toxicities of combining vorinostat and bortezomib as maintenance therapy after
      autologous stem cell transplant (ASCT) for NHL.

      SECONDARY OBJECTIVES:

      I. Ability to complete planned therapy.

      II. Time to disease progression, event-free survival.

      III. Overall survival.

      OUTLINE:

      All patients receive carmustine intravenously (IV) over 3 hours on day -7; cytarabine IV
      twice daily (BID) over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and
      melphalan IV over 30 minutes on day -2. Only patients with history of cluster of
      differentiation (CD)20+ NHL receive additional rituximab IV on days -19 and -12. Patients
      undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat
      orally (PO) once daily (QD) on days 1-14. Treatment with bortezomib and vorinostat repeats
      for total of 12 courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for at least 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2010</start_date>
  <primary_completion_date type="Actual">June 17, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant</measure>
    <time_frame>3 months after start of maintenance therapy</time_frame>
    <description>Number of patients on maintenance therapy post-transplant who experienced grade 3 or higher toxicity per NCI-Common Terminology Criteria for Adverse Events, version 3. The first three months of bortezomib and vorinostat therapy will be used as the time period to evaluate toxicity for stopping rules of the study. Toxicity that meets stopping rules will be determined based on the number of patients that are withdrawn from study for significant toxicity (grade IV, non-hematological, non-metabolic, non-peripheral neuropathy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Disease Progression</measure>
    <time_frame>3 Years Post-Transplant</time_frame>
    <description>(Not enough follow-up to report. 6/17/2018 is when this outcome measure will be met)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to Complete Planned 12 Cycles of Maintenance Therapy</measure>
    <time_frame>Approximately 12 months following start of maintenance therapy</time_frame>
    <description>Number of patients who completed all 12 cycles of maintenance therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 Years Post-Transplant</time_frame>
    <description>(Not enough follow-up to report. 6/17/2018 is when this outcome measure will be met)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>3 Years Post-Transplant</time_frame>
    <description>(Not enough follow-up to report. 6/17/2018 is when this outcome measure will be met)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Adult Diffuse Large B-Cell Lymphoma</condition>
  <condition>B-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>T-Cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo ASCT</description>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <other_name>BCNU</other_name>
    <other_name>Becenum</other_name>
    <other_name>Becenun</other_name>
    <other_name>BiCNU</other_name>
    <other_name>Bis(chloroethyl) Nitrosourea</other_name>
    <other_name>Bis-Chloronitrosourea</other_name>
    <other_name>Carmubris</other_name>
    <other_name>Carmustin</other_name>
    <other_name>Carmustinum</other_name>
    <other_name>FDA 0345</other_name>
    <other_name>Gliadel</other_name>
    <other_name>N,N'-Bis(2-chloroethyl)-N-nitrosourea</other_name>
    <other_name>Nitrourean</other_name>
    <other_name>Nitrumon</other_name>
    <other_name>SK 27702</other_name>
    <other_name>SRI 1720</other_name>
    <other_name>WR-139021</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>RTXM83</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemotherapy, ASCT, bortezomib, vorinostat))</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>Suberanilohydroxamic Acid</other_name>
    <other_name>Suberoylanilide Hydroxamic Acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  INCLUSION CRITERIA FOR AUTOLOGOUS TRANSPLANT

          -  Diagnosis of non-Hodgkin's lymphoma, transformed B-cell lymphoma, follicular lymphoma,
             mantle cell lymphoma, diffuse large B-cell or T-cell lymphoma, and deemed a candidate
             for autologous transplant

          -  American Heart Association class I: patients with cardiac disease but without
             resulting limitation of physical activity; ordinary physical activity does not cause
             undue fatigue, palpitation, dyspnea, or anginal pain; additionally, patients &gt; 60
             years of age must have a left ventricular ejection fraction of at least &gt;= 40%
             demonstrated by multi gated acquisition scan (MUGA) or echocardiogram (Echo)

          -  Total bilirubin =&lt; 1.5 mg/dL

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 3 x the upper
             limit of normal

          -  Creatinine clearance (CrCL) (calculated creatinine clearance is permitted) &gt; 40 mL/min

          -  Diffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in
             one second (FEV1), and forced vital capacity (FVC) &gt;= 50% of predicted (corrected for
             hemoglobin)

          -  Autologous graft with a minimum of &gt;= 3.0 x 10^6 CD34+ cells/kg; not CD34 selected

          -  Signed informed consent

          -  Female patients of childbearing potential has a negative serum pregnancy test
             beta-human chorionic gonadotropin (hCG)

          -  Female patient is either postmenopausal, free from menses for &gt;= 2 years, surgically
             sterilized, or willing to use 2 adequate barrier methods of contraception to prevent
             pregnancy or agrees to abstain from heterosexual activity throughout the study

          -  Male patient agrees to use an adequate method of contraception for the duration of the
             study

          -  INCLUSION CRITERIA FOR MAINTENANCE THERAPY

          -  30-120 days post ASCT for non-Hodgkin's lymphoma

          -  CrCL &gt;= 40 ml/min

          -  Platelets (PLT) &gt;= 75,000 cells/mm^3 for 5 days after recovery from ASCT nadir

          -  Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm^3 for 5 days after recovery from
             ASCT nadir

          -  Total bilirubin (TB) =&lt; 1.5 x upper limit of normal (ULN)

          -  AST/ALT =&lt; 2.5 x ULN

        Exclusion Criteria:

          -  EXCLUSION CRITERIA FOR AUTOLOGOUS TRANSPLANT

          -  Karnofsky performance score &lt; 70%

          -  Uncontrolled bacterial, viral, or fungal infection (currently taking medication and
             with progression or no clinical improvement)

          -  Pregnant or breastfeeding

          -  Fertile men and women unwilling to use contraceptive techniques from the time of
             transplant until one month post maintenance therapy

          -  Prior autologous or allogeneic hematopoietic stem cell transplantation (HSCT)

          -  Patients with evidence of myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML)
             or abnormal cytogenetics analysis indicative of MDS on the pre-transplant bone marrow
             examination

          -  Prolonged corrected QT interval (QTC) on electrocardiogram (EKG)

          -  Poorly-controlled diabetes mellitus (DM)

          -  &gt;= grade 2 peripheral neuropathy

          -  Prior history of human immunodeficiency virus (HIV) positivity or known history of
             hepatitis B or C

          -  Previous history of hypersensitivity to bortezomib, boron, or mannitol; known
             hypersensitivity to the components of study drug or its analogs

          -  Require therapeutic anticoagulation treatment, especially with Coumadin

          -  Patient who has had chemotherapy, radiotherapy, or biological therapy, within 30 days
             (42 days for nitrosoureas or mitomycin C) or who has not recovered from adverse events
             due to agents administered more than 30 days earlier

          -  Patient is currently participating or has participated in a study with an
             investigational compound or devise within 30 days of initial dosing with study drug(s)

          -  Patient had prior treatment with an histone deacetylase (HDAC) inhibitor (e.g.,
             romidepsin [Depsipeptide], NSC-630176, MS 275, LAQ-824, belinostat [PXD-101], LBH589,
             MGCD0103, CRA024781, etc); patients who have received compounds with HDAC
             inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not
             enroll in this study; patients who have received such compounds for other indications,
             e.g. valproic acid for epilepsy, may enroll after a 30-day washout period

          -  History of central nervous system (CNS) disease

          -  Symptomatic ascites or pleural effusions

          -  Patient has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial

          -  Patient is, at the time of signing informed consent, a regular user (including
             &quot;recreational use&quot;) of any illicit drugs, substance abuse or had a recent history
             (within the last year) of drug or alcohol abuse

          -  Patient with a history of a prior malignancy with the exception of complete resection
             of basal cell carcinoma or squamous cell carcinoma or an in situ malignancy;
             adequately treated localized prostate carcinoma with prostate-specific antigen (PSA) &lt;
             1.0; or who has undergone potentially curative therapy with no evidence of disease for
             five years, and/or who is deemed at low risk for recurrence by his/her treating
             physician

          -  Patient has a history or current evidence of any condition, therapy, or laboratory
             (lab) abnormality that might confound the results of the study, interfere with the
             patient's participation for the full duration of the study or is not in the best
             interest of the patient to participate

          -  Patient has a history of a gastrointestinal surgery or other procedures that might, in
             the opinion of the investigator, interfere with the absorption or swallowing of the
             study drugs

          -  EXCLUSION CRITERIA FOR MAINTENANCE THERAPY

          -  &gt;= grade 2 peripheral neuropathy within 14 days before beginning maintenance therapy

          -  Prolonged QTC

          -  Poorly-controlled DM

          -  Myocardial infarction (MI) with ASCT or developed dilated cardiomyopathy with ASCT

          -  Untreated systemic infection

          -  Potassium (K) and magnesium (Mg) &gt;= grade 2 toxicity

          -  Patient had myocardial infarction within 6 months prior to enrollment or has New York
             Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities; prior to study entry, any
             electrocardiogram (ECG) abnormality at screening must be documented by the
             investigator as not medically relevant

          -  Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol

          -  Female subject is pregnant or lactating; confirmation that the subject is not pregnant
             must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG)
             pregnancy test result obtained during screening; pregnancy testing is not required for
             postmenopausal or surgically sterilized women

          -  Female patients who are lactating or have a positive serum pregnancy test during the
             screening period, or a positive urine pregnancy test on day 1 before first dose of
             study drug, if applicable

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

          -  Diagnosed or treated for another malignancy within 3 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy

          -  Participation in clinical trials with other investigational agents not included in
             this trial, within 14 days of the start of this trial and throughout the duration of
             this trial

          -  Radiation therapy within 3 weeks before randomization; enrollment of subjects who
             require concurrent radiotherapy (which must be localized in its field size) should be
             deferred until the radiotherapy is completed and 3 weeks have elapsed since the last
             date of therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona Holmberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>March 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2017</results_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Leona Holmberg</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Autologous stem cell transplant</keyword>
  <keyword>NHL</keyword>
  <keyword>maintenance therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy, ASCT, Bortezomib, Vorinostat))</title>
          <description>All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT
Bortezomib: Given IV
Carmustine: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Melphalan: Given IV
Rituximab: Given IV
Vorinostat: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Maintenance Therapy Screen Fail</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy, ASCT, Bortezomib, Vorinostat))</title>
          <description>All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT
Bortezomib: Given IV
Carmustine: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Melphalan: Given IV
Rituximab: Given IV
Vorinostat: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="39" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant</title>
        <description>Number of patients on maintenance therapy post-transplant who experienced grade 3 or higher toxicity per NCI-Common Terminology Criteria for Adverse Events, version 3. The first three months of bortezomib and vorinostat therapy will be used as the time period to evaluate toxicity for stopping rules of the study. Toxicity that meets stopping rules will be determined based on the number of patients that are withdrawn from study for significant toxicity (grade IV, non-hematological, non-metabolic, non-peripheral neuropathy).</description>
        <time_frame>3 months after start of maintenance therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, ASCT, Bortezomib, Vorinostat))</title>
            <description>All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT
Bortezomib: Given IV
Carmustine: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Melphalan: Given IV
Rituximab: Given IV
Vorinostat: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant</title>
          <description>Number of patients on maintenance therapy post-transplant who experienced grade 3 or higher toxicity per NCI-Common Terminology Criteria for Adverse Events, version 3. The first three months of bortezomib and vorinostat therapy will be used as the time period to evaluate toxicity for stopping rules of the study. Toxicity that meets stopping rules will be determined based on the number of patients that are withdrawn from study for significant toxicity (grade IV, non-hematological, non-metabolic, non-peripheral neuropathy).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Disease Progression</title>
        <description>(Not enough follow-up to report. 6/17/2018 is when this outcome measure will be met)</description>
        <time_frame>3 Years Post-Transplant</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ability to Complete Planned 12 Cycles of Maintenance Therapy</title>
        <description>Number of patients who completed all 12 cycles of maintenance therapy.</description>
        <time_frame>Approximately 12 months following start of maintenance therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, ASCT, Bortezomib, Vorinostat))</title>
            <description>All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT
Bortezomib: Given IV
Carmustine: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Melphalan: Given IV
Rituximab: Given IV
Vorinostat: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Ability to Complete Planned 12 Cycles of Maintenance Therapy</title>
          <description>Number of patients who completed all 12 cycles of maintenance therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Completed 12 Cycles of Maintenance Therapy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unable to complete therapy due to relapse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Withdrawl at patient request</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unable to complete due to toxicities</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PI decision due to increasing creatinine levels</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patient left state</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>(Not enough follow-up to report. 6/17/2018 is when this outcome measure will be met)</description>
        <time_frame>3 Years Post-Transplant</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event-free Survival</title>
        <description>(Not enough follow-up to report. 6/17/2018 is when this outcome measure will be met)</description>
        <time_frame>3 Years Post-Transplant</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events will be evaluated according to criteria outlined in the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 3.0., except hematological toxicity. Grade 3 or higher reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy, ASCT, Bortezomib, Vorinostat))</title>
          <description>All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT
Bortezomib: Given IV
Carmustine: Given IV
Cytarabine: Given IV
Etoposide: Given IV
Melphalan: Given IV
Rituximab: Given IV
Vorinostat: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Transplant toxicity. One patient had both febrile neutropenia with transplant and pneumonia with maintenance therapy as two separate events.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter/atrial fibrillation</sub_title>
                <description>Transplant toxicity.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain/diarrhea</sub_title>
                <description>Maintenance therapy toxicity.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea, vomiting, and diarrhea requiring hospitalization</sub_title>
                <description>Transplant toxicity.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Transplant toxicity.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Maintenance therapy toxicity. One patient had both febrile neutropenia with transplant and pneumonia with maintenance therapy as two separate events.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <description>Maintenance therapy post-transplant adverse event. No patients died due to maintenance therapy.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea/Vomitting</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Auto GVHD</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Volume overload</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Maintenance therapy post-transplant adverse event. No patients died due to maintenance therapy.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Maintenance therapy post-transplant adverse event. No patients died due to maintenance therapy.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Maintenance therapy post-transplant adverse event. No patients died due to maintenance therapy.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Maintenance therapy post-transplant adverse event. No patients died due to maintenance therapy.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Peripheral neuropathy</sub_title>
                <description>Maintenance therapy post-transplant adverse event. No patients died due to maintenance therapy.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Autologous transplant adverse event. No patients died due to transplant therapy.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leona A. Holmberg</name_or_title>
      <organization>Fred Hutchinson Cancer Research Center</organization>
      <phone>206-667-6447</phone>
      <email>lholmber@fredhutch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

